Recombinant Human CD200 Protein (His & Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-0774
Recombinant Human CD200 Protein (His & Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-0774
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Tag | His&Fc |
Host Species | Human |
Accession | NP_005935.4 |
Synonym | MOX1, MOX2, MRC, OX-2, OX2 |
Background | CD2 (OX-2) is a cell surface glycoprotein that imparts immune privileges by suppressing alloimmune and autoimmune responses through its receptor, CD2R, expressed primarily on myeloid cells. Signals delivered through the CD2:CD2R axis have been shown to play an important role in the regulation of anti-tumor immunity, and overexpression of CD2 has been reported in a number of malignancies, including CLL, as well as on cancer stem cells. The role of CD2-CD2R signaling in immune regulation of the central nervous system has become a popular field of research in recent years. Many studies have shown that there is a close correlation between CD2-CD2R, microglia activation, and Parkinson's disease (PD). The ability of CD2 to suppress myeloid cell activation is critical for maintaining normal tissue homeostasis but may also enhance the survival of migratory neoplastic cells. CD2 and CD2R associate via their respective N-terminal Ig-like domains. CD2 has been characterized as an important immunoregulatory molecule, increased expression of which can lead to decreased transplant rejection, autoimmunity, and allergic disease. Elevated CD2 expression has been reported to be associated with poor prognosis in a number of human malignancies. In addition, CD2 also plays an important role in prevention of graft rejection, autoimmune diseases and spontaneous abortion.Immune CheckpointImmunotherapyCancer ImmunotherapyTargeted Therapy |
Description | A DNA sequence encoding the human CD200 (NP_005935.4) extracellular domain (Met 1-Gly 232) was fused with the C-terminal His-tagged Fc region of human IgG1 at the C-terminus. |
Source | HEK293 |
Predicted N Terminal | Gln 31 |
AA Sequence | Met 1-Gly 232 |
Molecular Weight | The recombinant human CD200/Fc is a disulfide-linked homodimer. The reduced monomer consists of 450 a.a. and has a predicted molecular mass of 50.5 kDa. As a result of glycosylation, the apparent molecular mass of rh CD200/Fc monomer is approximately 65-70 kDa in SDS-PAGE under reducing conditions. |
Purity | >95% as determined by SDS-PAGE |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
Bioactivity | Measured by its binding ability in a functional ELISA. Immobilized human CD200R1 at 1 ug/ml (100 ul/well) can bind human CD200 Fc Chimera with a linear range of 0.12-16 ng/ml. |
Formulation | Lyophilized from sterile PBS, pH 7.4. |
Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
Usage | For Research Use Only |
Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |